# Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg

> **NCT01762800** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 407 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone propionate/salmeterol 50/250mcg
- **DRUG:** fluticasone propionate/salmeterol placebo
- **DRUG:** tiotropium bromide 18mcg
- **DRUG:** tiotropium bromide placebo
- **DRUG:** fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg

## Key facts

- **NCT ID:** NCT01762800
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2016-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01762800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01762800, "Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01762800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*